Brief: CStone Pharmaceuticals Enters Collaboration For Nofazinlimab In Mainland China
20/12/2023 10:23
Dec 20 (Reuters) - CStone Pharmaceuticals 2616.HK :
* ENTERED INTO A STRATEGIC COLLABORATION FOR NOFAZINLIMAB IN
MAINLAND CHINA WITH 3SBIO INC
* RECENTLY ESTABLISHED COMMERCIAL COLLABORATIONS WITH TWO
COMPANIES
* GRANTED 3SBIO EXCLUSIVE RIGHTS FOR DEVELOPMENT,
REGISTRATION,
MANUFACTURING, AND COMMERCIALIZATION OF NOFAZINLIMAB
* CSTONE WILL RETAIN RIGHTS TO NOFAZINLIMAB OUTSIDE OF
MAINLAND
CHINA
Further company coverage: 2616.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CStone Pharmaceuticals
See all newsBrief: CStone Pharmaceuticals Says CEO Purchases 496,000 Shares For Over HK$2.7 Million From Sept 17-22
Brief: CStone Pharmaceuticals Posts HY Loss Of Rmb252.3 Million
China's CStone Pharmaceuticals H1 revenue soars on drug sales
Brief: Cstone Pharmaceuticals Receives NMPA IND Approval For CS5007 In China
Brief: CStone Pharmaceuticals Says Directors And Senior Management Purchase 2.4 Million Shares In June 2026